# Myasthenia gravis research and treatment in Italy

> Developing situation record from CLSTR: https://clstr.news/situations/myasthenia-gravis-research-in-italy
> Updated: 2026-10-27T14:02:00.000Z. Sources: 13. Developments: 2.

Efforts to manage and understand Myasthenia gravis, a rare autoimmune disease causing muscle weakness, have progressed through various clinical initiatives in Italy.

Initial efforts included the ‘Training Xperience’ project, a field training initiative involving three major neurological centers in Lombardy. This project focused on personalizing therapeutic pathways and integrating different treatment modalities into clinical practice.

Building on these efforts, the Poema study was launched to gather real-world evidence on the disease. This prospective study evaluates the response to efgartigimod treatment while examining psychological well-being, autonomy, and quality of life. The research involves 40 reference centers across Italy and monitors 100 patients over a 12-month period.

At the 56th Congress of the Italian Society of Neurology, new findings from a multicenter study involving 14 centers were presented by neurologist Nicasio Rini. The research indicates that zilucoplan, a complement inhibitor, effectively improves patients' clinical conditions and quality of life. The treatment has been associated with a ‘progressive reduction in daily corticosteroid dosages’ and a ‘drastic decrease in hospitalizations and rescue therapies’.

## Claims

- The Poema study is a prospective real-world evidence research project in Italy. (reported by 3 sources)
- The study evaluates the response to efgartigimod treatment. (reported by 3 sources)
- The research involves 40 reference centers across Italy. (reported by 3 sources)
- The study includes 100 recruited patients. (reported by 3 sources)
- Patients will be followed for a period of 12 months. (reported by 3 sources)
- Enrollment for the study has reached 50 percent. (reported by 3 sources)
- An Investigator Meeting was held in Turin to share progress. (reported by 3 sources)
- Myasthenia Gravis is an autoimmune disease causing muscle weakness and fatigue. (reported by 3 sources)

## Timeline

### 2026-10-27: Italy advances research and treatments for Myasthenia Gravis

Italian medical researchers are reporting improved patient outcomes with zilucoplan and launching the Poema study to evaluate the socio-sanitary and psychological impacts of efgartigimod on Myasthenia Gravis.

13 sources. https://clstr.news/cluster/italy-launches-poema-study-on-myasthenia-gravis-impact

### 2026-10-02: Myasthenia gravis affects 15,000 people in Italy

Myasthenia gravis affects over 15,000 people in Italy. New clinical training initiatives in Lombardy aim to improve care through personalized treatment and better monitoring of this chronic autoimmune disease.

3 sources. https://clstr.news/cluster/myasthenia-gravis-affects-15000-people-in-italy

---
Cite as: Myasthenia gravis research and treatment in Italy. CLSTR, https://clstr.news/situations/myasthenia-gravis-research-in-italy
